Prometheus Biosciences Inc

Great News! Now you can buy fractional shares of Prometheus Biosciences Inc

What is Fractional Shares?

Fractional shares are pieces of one full share of a company or exchange-traded fund (ETF).

In INDmoney, you can buy Prometheus Biosciences Inc stock in any dollar amount, or any other stock you want.

$10

$50

$100

RXDX

Prometheus Biosciences Inc (RXDX)

Q: What is Prometheus Biosciences Inc (RXDX) share price today?

Prometheus Biosciences Inc (RXDX) share price today is $34.3

Q: Can Indians buy Prometheus Biosciences Inc (RXDX) shares?

Yes, Indians can buy Prometheus Biosciences Inc (RXDX) shares. As per RBI rule, an Indian citizen can invest 250,000 dollars a year in foreign markets.

Q: How can I buy Prometheus Biosciences Inc (RXDX) shares from India?

Three ways to invest in Prometheus Biosciences Inc (RXDX) stocks from India are 1.Investment through apps: INDmoney is one of the leading apps that help you invest in Prometheus Biosciences Inc (RXDX) stocks from India 2.Investment through Indian brokers tied up with a foreign broker 3.Investment by opening an account with a Foreign broker

Q: Can Fractional shares of Prometheus Biosciences Inc (RXDX) be purchased?

You can buy just a fraction of Prometheus Biosciences Inc (RXDX) shares.

Q: What are the documents required to start investing in Prometheus Biosciences Inc (RXDX) stocks?

You will need a proof of Identification (PAN, Aadhaar etc) and proof of address (Aadhaar, Voter ID etc) to invest in Prometheus Biosciences Inc (RXDX) stocks . The entire process is paperless and can be completed seamlessly.

$34.35.41%▲

Key Stats

Open	$31.76
Today Low/High	$31.63 / $34.49
52 Week Low/High	$16.11 / $40.49
Market Cap	$1.33B

Company Details

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.